Ken Griffin Ocuphire Pharma, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,000 shares of OCUP stock, worth $2,780. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000
Previous 3,600
44.44%
Holding current value
$2,780
Previous $7,000
57.14%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding OCUP
# of Institutions
42Shares Held
2.74MCall Options Held
2KPut Options Held
2K-
Vanguard Group Inc Valley Forge, PA992KShares$1.38 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA266KShares$369,5370.0% of portfolio
-
Rice Hall James & Associates, LLC224KShares$310,7880.02% of portfolio
-
Richmond Brothers, Inc. Jackson, MI191KShares$265,9120.6% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX164KShares$227,5990.01% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $28.6M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...